| Comprehensive control of human papillomavirus infections and related diseases FX Bosch, TR Broker, D Forman, AB Moscicki, ML Gillison, J Doorbar, ... Vaccine 31, H1-H31, 2013 | 837 | 2013 |
| Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries M Brisson, JJ Kim, K Canfell, M Drolet, G Gingras, EA Burger, D Martin, ... The Lancet 395 (10224), 575-590, 2020 | 772 | 2020 |
| Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries K Canfell, JJ Kim, M Brisson, A Keane, KT Simms, M Caruana, EA Burger, ... The Lancet 395 (10224), 591-603, 2020 | 539 | 2020 |
| Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies Collaborative Group on Epidemiological Studies of Ovarian Cancer The Lancet 385 (9980), 1835-1842, 2015 | 535 | 2015 |
| Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study KT Simms, J Steinberg, M Caruana, MA Smith, JB Lew, I Soerjomataram, ... The lancet oncology 20 (3), 394-407, 2019 | 486 | 2019 |
| The projected timeframe until cervical cancer elimination in Australia: a modelling study MT Hall, KT Simms, JB Lew, MA Smith, JML Brotherton, M Saville, ... The Lancet Public Health 4 (1), e19-e27, 2019 | 464 | 2019 |
| Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic … M Brisson, É Bénard, M Drolet, JA Bogaards, I Baussano, S Vänskä, M Jit, ... The Lancet Public Health 1 (1), e8-e17, 2016 | 338 | 2016 |
| The IARC perspective on cervical cancer screening V Bouvard, N Wentzensen, A Mackie, J Berkhof, J Brotherton, ... New England Journal of Medicine 385 (20), 1908-1918, 2021 | 257 | 2021 |
| Towards the global elimination of cervical cancer K Canfell Papillomavirus research 8, 100170, 2019 | 225 | 2019 |
| The burden of cervical cancer in China: synthesis of the evidence JF Shi, K Canfell, JB Lew, YL Qiao International journal of cancer 130 (3), 641-652, 2012 | 208 | 2012 |
| Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia K Canfell, E Banks, AM Moa, V Beral Medical Journal of Australia 188 (11), 641-644, 2008 | 208 | 2008 |
| Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study KT Simms, SJB Hanley, MA Smith, A Keane, K Canfell The Lancet Public Health 5 (4), e223-e234, 2020 | 204 | 2020 |
| Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National … JB Lew, KT Simms, MA Smith, M Hall, YJ Kang, XM Xu, M Caruana, ... The Lancet Public Health 2 (2), e96-e107, 2017 | 196 | 2017 |
| The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort … HC Kitchener, K Canfell, C Gilham, A Sargent, C Roberts, M Desai, J Peto Health Technology Assessment (Winchester, England) 18 (23), 1, 2014 | 184 | 2014 |
| Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case–control study M Urban, E Banks, S Egger, K Canfell, D O'Connell, V Beral, F Sitas PLoS medicine 9 (3), e1001182, 2012 | 181 | 2012 |
| 2020 list of human papillomavirus assays suitable for primary cervical cancer screening M Arbyn, M Simon, E Peeters, L Xu, CJLM Meijer, J Berkhof, K Cuschieri, ... Clinical Microbiology and Infection 27 (8), 1083-1095, 2021 | 170 | 2021 |
| Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study JB Lew, DJB St John, XM Xu, MJE Greuter, M Caruana, DR Cenin, E He, ... The Lancet Public Health 2 (7), e331-e340, 2017 | 167 | 2017 |
| Is it possible to halve the incidence of liver cancer in China by 2050? JF Shi, M Cao, Y Wang, FZ Bai, L Lei, J Peng, E Feletto, K Canfell, C Qu, ... International journal of cancer 148 (5), 1051-1065, 2021 | 156 | 2021 |
| Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis Z Zou, CK Fairley, JJ Ong, J Hocking, K Canfell, X Ma, EPF Chow, X Xu, ... The Lancet Global Health 8 (10), e1335-e1344, 2020 | 143 | 2020 |
| Modeling preventative strategies against human papillomavirus-related disease in developed countries K Canfell, H Chesson, SL Kulasingam, J Berkhof, M Diaz, JJ Kim Vaccine 30, F157-F167, 2012 | 143 | 2012 |